drugset
drugset / Trial / NCT06979076

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL

NCT06979076 ↗

Phase 1/2 Not yet recruiting 12 enrolled MingSight Pharmaceuticals, Inc
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Timeline

Start
2026-07
Primary completion
2028-09
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MS-553 Unknown — Oral

Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma